Skip to main content

Table 3 Efficacy endpoints at week 16 by anti-TNF status

From: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Endpoints Secukinumab IV-300 mg Secukinumab IV-150 mg Placebo
Anti-TNF-naïve N = 57 N = 57 N = 59
ASAS20, n (%) 37 (64.9)§ 36 (63.2) 23 (39.0)
ASAS40, n (%) 25 (43.9) 25 (43.9) 14 (23.7)
hsCRP (post-baseline/baseline ratio), LS mean change ± SE 0.43 ± 1.1* 0.51 ± 1.1 0.91 ± 1.1
ASAS 5/6, n (%) 24 (42.1) 26 (45.6)§ 11 (18.6)
BASDAI, LS mean change ± SE -3.2 ± 0.3§ -2.6 ± 0.3 -1.9 ± 0.3
ASAS partial remission, n (%) 12 (21.1)§ 6 (10.5) 1 (1.7)
Anti-TNF-IR N = 19 N = 17 N = 17
ASAS20, n (%) 9 (47.4) 7 (41.2) 5 (29.4)
ASAS40, n (%) 7 (36.8) 5 (29.4) 2 (11.8)
hsCRP (post-baseline/baseline ratio), LS mean change ± SE 0.57 ± 1.2§ 0.58 ± 1.3§ 1.5 ± 1.2
ASAS 5/6, n (%) 6 (31.6) 5 (29.4) 0
BASDAI, LS mean change ± SE -1.8 ± 0.6 -2.2 ± 0.6 -0.9 ± 0.6
ASAS partial remission, n (%) 4 (21.1) 1 (5.9) 0
  1. Non-responder imputation (binary variables) and mixed-model repeated measures (continuous variables) analyses are presented
  2. TNF tumor necrosis factor, N number of patients, ASAS Assessment of SpondyloArthritis international Society, hsCRP high-sensitivity C-reactive protein, LS least squares, SE standard error, BASDAI Bath Ankylosing Spondylitis Disease Activity Index
  3. P < 0.05, § P < 0.01, P < 0.001, * P < 0.0001 vs placebo. P-values are unadjusted